AbbVie: Here’s How It Could Differentiate Itself From Gilead

By early next week, AbbVie (ABBV) is widely expected to get approval for its hepatitis-c treatment, one that will compete with Gilead Sciences’ (GILD) Harvoni and Sovaldi. UBS analyst Marc Goodman says the only question is the treatment duration and the price: Approval is not really a debate, in our view, given the quality of [...]